ERBB2 and cancer: Moreover, preclinical investigations suggested that combination strategies, including the concomitant inhibition of HER2 and other oncotargets (such as PI3K and MEK), are able to induce colorectal cancer stem cell death, leading to cancer regression in xenograft models [143].